WO2011045810A1 - Compositions pharmaceutiques contenant de la taurine et de la race-méthionine pour le traitement de l'alcoolisme - Google Patents

Compositions pharmaceutiques contenant de la taurine et de la race-méthionine pour le traitement de l'alcoolisme Download PDF

Info

Publication number
WO2011045810A1
WO2011045810A1 PCT/IN2010/000530 IN2010000530W WO2011045810A1 WO 2011045810 A1 WO2011045810 A1 WO 2011045810A1 IN 2010000530 W IN2010000530 W IN 2010000530W WO 2011045810 A1 WO2011045810 A1 WO 2011045810A1
Authority
WO
WIPO (PCT)
Prior art keywords
alcohol
methionine
taurine
liver
race
Prior art date
Application number
PCT/IN2010/000530
Other languages
English (en)
Other versions
WO2011045810A4 (fr
Inventor
Kamlesh Rajnikant Zota
Sanjay Agrawal
Ketan Chandulal Zota
Manukant Chandulal Zota
Himanshu Muktilal Zota
Original Assignee
Zota Health Care Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zota Health Care Limited filed Critical Zota Health Care Limited
Publication of WO2011045810A1 publication Critical patent/WO2011045810A1/fr
Publication of WO2011045810A4 publication Critical patent/WO2011045810A4/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]

Definitions

  • compositions containing taurine and race-methionine for the treatment of alcoholism are provided.
  • the invention relates generally to pharmaceutical composition containing taurine and race-methionine for the treatment of alcoholism.
  • a nutritional product for cancer patients comprising, as per caloric requirement, a low concentration of carbohydrate, a high concentration of fat and an imbalance of amino acids wherein L-phenylalanine, L-tyrosine and L-methionine are present in the below normal concentrations and L-leucine is present in substantial excess of normal concentrations to suppress cancer growth and as an adjunct to conventional cancer therapies
  • compositions and methods of administration are designed to effectively elevate and sustain blood levels of said compounds in turn enhancing the body's natural chondroprotective mechanisms while providing an efficient delivery mechanism which optimizes cellular uptake of glucosamine and chondroitin.
  • This process of forming specified synergistic relationships between vital metabolic precursors increases the body's production of proteoglycans, chondrocytes, hyalauron glycosaminoglycans and collagen, facilitating the repair and regeneration of articular cartilage and symptomatic relief from pain and inflammation associated with articular degeneration.
  • the present invention relates to a health supplement food utilizing, in particular, branched amino acids from among essential amino acids. More specifically, the present invention relates to: a health supplement food comprising branched chain amino acids (hereinafter, referred to as LIV) composed of leucine (L), isoleucine (I) and valine (V) which is made to have a composition similar to essential amino acids contained in naturally-occurring milk, eggs, soybeans, beef and the like, and enhancing instant impact power under anaerobic conditions, via addition of L- glutamine and taurine which are essentially required when a person is exposed to excessive exercise, stress or overwork; a health supplement food for improving a weak constitution, comprising herbal materials such as ginseng, red ginseng and Acanthopanax; and a diet food or beverage further comprising dietary fibers such as inulin, polydextrose and crystalline cellulose, and carnitine and hydroxy citric acid.
  • LIV branched chain amino acids
  • LIV branched
  • An exemplary dried, meat- based product includes meat and plant seed where the plant seed comprises at least approximately 3% caffeine by weight.
  • an exemplary product includes guarana plant seed.
  • plant seed may be provided as a powder
  • compositions comprising one or more ionic salts, each of said ionic salts consisting of a bicarbonate anion and a cation selected from the group consisting of an amino acid, an amino acid derivative, a di- peptide and a tri-peptide, and to methods of making and using said compositions.
  • the present invention is basically based on treatment of alcoholism by pharmaceutical composition.
  • Alcoholism is a disease. It is often diagnosed more through behaviors and adverse effects on functioning than by specific medical symptoms. Alcoholics, when confronted, will often deny excess consumption of alcohol. Alcoholism is a diverse disease and is often influenced by the alcoholic's personality as well as by oilier factors. Therefore, signs and symptoms often vary from person to person. There are, however, certain behaviors and signs that indicate someone may have a problem with alcohol.
  • Late signs and symptoms include medical conditions such as pancreatitis, gastritis, cirrhosis, neuropathy, anemia, cerebellar atrophy, alcoholic cardiomyopathy (heart disease), Wernicke's encephalopathy (abnormal brain functioning), Korsakoff s dementia, central pontine myelinolysis (brain degeneration), seizures, confusion, malnutrition, hallucinations, peptic ulcers, and gastrointestinal bleeding.
  • EFFECT OF ALCOHOLISM IN LIVER- Alcohol abuse can cause a condition called "fatty liver” or another called “alcohol hepatitis”— both of which can be treated, but only if alcohol consumption is stopped. If drinking continues, these conditions will cause cirrhosis of the liver. Alcoholism is called a progressive disease, meaning that over time the symptoms and effects of drinking alcohol become more intense and severe. The symptoms in the early stages differ from those during later stages as the disease progresses from binge drinking to alcohol abuse to alcohol dependence.
  • the liver detoxifies poisons, both those produced by the body and those from outside; filters bacteria from the blood; regulates fat metabolism; stores and manufactures vitamins; regulates and manufactures cholesterol and fats; synthesizes proteins; maintains the body's water and salt balance; secretes bile for the digestion of fat; stores energy (in the form of glycogen) helps regulate overall body metabolism; transforms the highly toxic ammonia (produced by exercise and by metabolism of proteins) into urea which is eliminated in the urine; manufactures lipoproteins for fat and cholesterol transport; and metabolizes alcohol.
  • Information dissemination This strategy provides awareness and knowledge of the nature and extent of alcohol, tobacco, and other drug use, abuse, and addiction and their effects on individuals, families, and communities, as well as information to increase perceptions of risk. It also provides knowledge and awareness of prevention policies, programs, and services. It helps set and reinforce norms (for example, underage drinking and drug dealers will not be tolerated in this neighborhood).
  • Prevention education This strategy aims to affect critical life and social skills, including decision making, refusal skills, critical analysis (for example, of media messages), and systematic and judgmental abilities.
  • This strategy aims to enhance the ability of the community to provide prevention and treatment services to alcohol, tobacco, and other drug use disorders more effectively. Activities include organizing, planning, enhancing efficiency and effectiveness of services implementation, interagency collaboration, coalition building, and networking. Building healthy communities encourages healthy lifestyle choices. Environmental approach. This strategy sets up or changes written and unwritten community standards, codes, and attitudes— influencing incidence and prevalence of alcohol, tobacco, and other drug use problems in the general population. Included are laws to restrict availability and access, price increases, and community-wide actions.
  • the main object of the invention is to provide the composition of pharmaceutical which is comparatively more effective than others as it contains taurine and race- methionin.
  • Taurine or 2-aminoethanesulfonic acid, is an organic acid. Taurine can either promote or repress the reward effects associated with alcohol; the delineating factor being the amount of alcohol consumed its role in alcoholism. Its major metabolite taurocholic acid is responsible for the metabolic conversion of alcohol. Race Methionine has antioxidant properties. It prevents lower cholesterol levels by increasing the liver's production of lecithin, reduces liver fat and protects the kidneys.
  • This invention is based on a pharmaceutical composition containing taurine and race-methionine for treating alcoholism. Both are helpful for protection to liver by alcohol.
  • the liver is the largest glandular organ of the body.
  • the liver has many functions. Some of the functions are: to produce substances that break down fats, convert glucose to glycogen, produce urea (the main substance of urine), make certain amino acids (the building blocks of proteins), filter harmful substances from the blood (such as alcohol), storage of vitamins and minerals (vitamins A, D, K and Bl 2) and maintain a proper level or glucose in the blood.
  • the liver is also responsible for producing cholesterol. It produces about 80% of the cholesterol in your body.
  • the main disease of liver is Alcohol alters the metabolism of the liver, which can have overall detrimental effects if alcohol is taken over long periods of time
  • alcohol can cause:
  • Taurine or 2-aminoethanesulfonic acid- It is an organic acid. Taurine is one of the most abundant amino acids in the body . It is also a major constituent of bile and can be found in the lower intestine and in small amounts in the tissues of many animals, including humans. Taurine is a derivative of the sulfur-containing (sulfhydryl) amino acid, cysteine. Taurine is one of the few known naturally occurring sulfonic acids. It has a number of roles regarding normal functioning of the brain, heart, gallbladder, eyes and vascular system. It functions to facilitate the movement of mineral and salt ions in and out of the cells and to stabilize cell membranes.
  • Ca N- acetylhomotaurinate (Ca AOTA) appears to be the most active anti-acetaldehyde and anti-alcohol agent.
  • Large numbers of 1 taurine derivatives have been reported in the literature with partial to marked activity.
  • Taurine derivatives like taltrimide, acamprosate and tauromustine are already in the market as anti-convulsant, anti-alcoholic and anti-cancer agents.
  • Taurine derivatives like taltrimide, acamprosate and tauromustine are already in the market as anti-convulsant, anti-alcoholic and anticancer agents.
  • Taurine can either promote or repress the reward effects associated with alcohol, the delineating factor being the amount of alcohol consumed. Its major metabolite taurocholic acid is responsible for the metabolic conversion of alcohol.
  • the correlation of taurine with alcohol consumption scientists synthesized the drug acamprosate, the calcium salt of N-acetyl-homotaurinate. It is the first agent specifically designed to maintain abstinence in alcohol-dependent patients who have completed detoxification. It interacts with glutamanergic neurotransmission channels (NMDA receptors) to reduce calcium flux., resulting in a depressed interest in alcohol consumption.Acomprosate decreases glutamate elevations that are characteristic of alcohol withdrawal.
  • NMDA receptors glutamanergic neurotransmission channels
  • Hepatic steatosis 'fatty liver'
  • lipid peroxidation by administering alcohol .
  • hepatic steatosis was greatly reduced and lipid per oxidation completely prevented.
  • Fatty liver was prevented in animals receiving taurine supplementation.
  • the protective effect of taurine was attributed to the potential of taurine conjugated bile acids (particularly taurocholic acid) to inhibit adverse enzymatic functions associated with alcohol consumption. This elucidates the very crucial tasks that taurine performs to protect against the deleterious effects of chronic alcohol consumption.
  • Methionine is one of the three amino acids needed by the body to manufacture Creatine, an amino acid essential for energy production and muscle building
  • Methionine is a natural chelating agent for heavy metals. It regulates the formation of ammonia and creates ammonia-free urine, which reduces bladder irritation.
  • Methionine is used in the liver as a detoxifying agent. It has also been used to treat depression, arthritis pain and chronic liver disease. Procedure of Manufacturing

Abstract

La présente invention concerne des compositions pharmaceutiques pour le traitement de l'alcoolisme, les compositions contenant de la taurine et de la race-méthionine. La taurine peut soit favoriser, soit réprimer les effets de récompense associés à l'alcool ; le facteur délimitant étant la quantité d'alcool consommée, son rôle dans l'alcoolisme. Son métabolite principal, l'acide taurocholique, est responsable de la conversion métabolique de l'alcool. La race-méthionine possède des propriétés antioxydantes. Elle empêche la baisse des taux de cholestérol en augmentant la production hépatique de lécithine, réduit la graisse hépatique.
PCT/IN2010/000530 2009-08-13 2010-08-10 Compositions pharmaceutiques contenant de la taurine et de la race-méthionine pour le traitement de l'alcoolisme WO2011045810A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1868/MUM/2009 2009-08-13
IN1868MU2009 2009-08-13

Publications (2)

Publication Number Publication Date
WO2011045810A1 true WO2011045810A1 (fr) 2011-04-21
WO2011045810A4 WO2011045810A4 (fr) 2011-07-28

Family

ID=43719467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000530 WO2011045810A1 (fr) 2009-08-13 2010-08-10 Compositions pharmaceutiques contenant de la taurine et de la race-méthionine pour le traitement de l'alcoolisme

Country Status (1)

Country Link
WO (1) WO2011045810A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013124860A1 (fr) * 2012-02-23 2013-08-29 Zota Health Care Ltd Formulation revitalisante puissante
WO2015177805A1 (fr) * 2014-05-19 2015-11-26 Zota Health Care Ltd Combinaison de taurine et de raceméthionine pour le traitement de maladies hépatiques

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817695A (en) 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
US5906811A (en) 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
EP1408988A1 (fr) 1999-11-02 2004-04-21 Shawn Paul Madere Composition de complementations administrees par voie orale pour reparer le cartilage articulaire
WO2006062273A1 (fr) 2004-12-10 2006-06-15 Se-Gyu Kim Complement alimentaire d'acides amines ramifies
US20070202215A1 (en) * 2006-02-28 2007-08-30 Zahramehran Salari Lak Dietary nutritional supplements for persons consuming alcohol products
WO2007114945A2 (fr) * 2006-04-04 2007-10-11 Hill's Pet Nutrition, Inc. Compositions et procedes visant a accroitre le statut antioxydant des animals
WO2007115112A2 (fr) 2006-03-29 2007-10-11 Brian Levin Produits de viande séchée comprenant au moins un stimulant
US20090005320A1 (en) 2008-09-02 2009-01-01 Bruce Kneller Compositions comprising amino acid bicarbonate and methods of use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5906811A (en) 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5817695A (en) 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
EP1408988A1 (fr) 1999-11-02 2004-04-21 Shawn Paul Madere Composition de complementations administrees par voie orale pour reparer le cartilage articulaire
WO2006062273A1 (fr) 2004-12-10 2006-06-15 Se-Gyu Kim Complement alimentaire d'acides amines ramifies
US20070202215A1 (en) * 2006-02-28 2007-08-30 Zahramehran Salari Lak Dietary nutritional supplements for persons consuming alcohol products
WO2007115112A2 (fr) 2006-03-29 2007-10-11 Brian Levin Produits de viande séchée comprenant au moins un stimulant
WO2007114945A2 (fr) * 2006-04-04 2007-10-11 Hill's Pet Nutrition, Inc. Compositions et procedes visant a accroitre le statut antioxydant des animals
US20090005320A1 (en) 2008-09-02 2009-01-01 Bruce Kneller Compositions comprising amino acid bicarbonate and methods of use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALCOHOLISM, CLINICAL AND EXPERIMENTAL RESEARCH APR 1989 LNKD- PUBMED:2658650, vol. 13, no. 2, April 1989 (1989-04-01), pages 164 - 171, ISSN: 0145-6008 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; April 1989 (1989-04-01), TABAKOFF B ET AL: "Methionine lowers circulating levels of acetaldehyde after ethanol ingestion.", XP002629096, Database accession no. NLM2658650 *
GUPTA ET AL: "Taurine analogues; a new class of therapeutics : retrospect and prospects", CURRENT MEDICINAL CHEMISTRY,, vol. 12, 1 January 2005 (2005-01-01), pages 2021 - 2039, XP002534926, DOI: DOI:10.2174/0929867054546582 *
KERAI M D ET AL: "Reversal of ethanol-induced hepatic steatosis and lipid peroxidation by taurine: a study in rats.", ALCOHOL AND ALCOHOLISM (OXFORD, OXFORDSHIRE) 1999 JUL-AUG LNKD- PUBMED:10456581, vol. 34, no. 4, July 1999 (1999-07-01), pages 529 - 541, XP002629095, ISSN: 0735-0414 *
LIEBER C S: "Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis", ALCOHOL, PERGAMON PRESS, LONDON, GB, vol. 34, no. 1, 1 August 2004 (2004-08-01), pages 9 - 19, XP004721099, ISSN: 0741-8329, DOI: DOI:10.1016/J.ALCOHOL.2004.07.008 *
LIEBER C S: "Liver diseases by alcohol and hepatitis C: Early detection and new insights in pathogenesis lead to improved treatment", AMERICAN JOURNAL ON ADDICTIONS 2001 US LNKD- DOI:10.1080/10550490150504128, vol. 10, no. SUPPL., 2001, pages 29 - 50, XP002629097, ISSN: 1055-0496 *
MASON B J ET AL: "Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials.", CNS SPECTRUMS FEB 2000 LNKD- PUBMED:18296999, vol. 5, no. 2, February 2000 (2000-02-01), pages 58 - 69, XP009146122, ISSN: 1092-8529 *
WU GAOFENG ET AL: "Effect of taurine on alcoholic liver disease in rats.", AMINO ACIDS MAR 2009 LNKD- PUBMED:18509591, vol. 36, no. 3, March 2009 (2009-03-01), pages 457 - 464, XP002629094, ISSN: 1438-2199 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013124860A1 (fr) * 2012-02-23 2013-08-29 Zota Health Care Ltd Formulation revitalisante puissante
WO2015177805A1 (fr) * 2014-05-19 2015-11-26 Zota Health Care Ltd Combinaison de taurine et de raceméthionine pour le traitement de maladies hépatiques

Also Published As

Publication number Publication date
WO2011045810A4 (fr) 2011-07-28

Similar Documents

Publication Publication Date Title
US10016450B2 (en) Anti-glycation methods and compositions
US8329227B2 (en) Compositions for improving mental performance
US5597585A (en) Vitamin/mineral composition
Kato-Kataoka et al. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints
Patel et al. Safety assessment of pomegranate fruit extract: acute and subchronic toxicity studies
US5626849A (en) Weight loss composition for burning and reducing synthesis of fats
Ofoedu et al. Revisiting food-sourced vitamins for consumer diet and health needs: a perspective review, from vitamin classification, metabolic functions, absorption, utilization, to balancing nutritional requirements
EP2683373B1 (fr) Agent orthomoléculaire utilisé contre les conséquences de la consommation d'alcool
RU2658380C1 (ru) Напиток для улучшения состояния кожи и суставов
WO2019053580A1 (fr) Composition de boisson énergétique
Hemat Principles of orthomolecularism
EP1469746A2 (fr) Composition de complement alimentaire
WO2011045810A1 (fr) Compositions pharmaceutiques contenant de la taurine et de la race-méthionine pour le traitement de l'alcoolisme
GB2585619A (en) A supplement
EP3503745B1 (fr) Complément alimentaire macro/micronutritionnel pour patients subissant une dialyse rénale
Ebuehi et al. Effect of zinc deficiency on memory, oxidative stress and blood chemistry in rats
KR20140017979A (ko) 중장년층용 비타 하이브리드 정제 및 그 제조 방법
DE10158498A1 (de) Nahrungsergänzungspräparat
Jodh et al. An Updated Review on Vitamin C-An Excellent Drug Having a Great Scavenging Property
JPH09132531A (ja) 流動食添加用組成物及び流動食
KR20120110955A (ko) 타우린, 이노시톨, 비타민ｃ, 비타민 ｂ군 및 요오드화칼륨을 주성분으로 함유하는 기능성 음료조성물
US10485783B1 (en) Methods and compositions for reducing or eliminating symptoms of withdrawal from drugs and alcohol
DE202016007024U1 (de) Ursachen und Abhilfe der Alzheimer-Symptome
Górska et al. The Effects of the Action of Chromium, Aluminum, Nickel and Iron on Human Fibroblast and Stem Cell Cultures
WO2007112963A1 (fr) Nouvelle utilisation de l'ascorbigène

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10782723

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10782723

Country of ref document: EP

Kind code of ref document: A1